The U.S. Food and Drug Administration has approved Enhertu (trastuzumab deruxtecan) for the treatment of adult patients with ...

The PATHWAY HER2 (4B5) test is now FDA-approved to assess HER2-ultralow status in metastatic breast cancer, expanding its ...

As monotherapy for treatment of adult patients with advanced NSCLC with activating EGFR exon 20 insertion mutations, after failure of platinum-based therapy.

such as increasing the function of oestrogen receptor-α and E2F1, the activity of the insulin-like growth factor 1 (IGF1) signalling pathway, epidermal growth factor receptor (EGFR) and ERBB2 ...

growth and branching, survival, and differentiation. These processes are primarily regulated by receptor tyrosine kinase signaling pathways and transcription factors expressed in the UB (Table 2).

ER, estrogen receptor; ERBB4, epidermal growth factor receptor 4; ERK ... activation of the G αi or G αq GPCR signaling pathway is thought to increase the phosphorylation of STAT5, and the effects of ...

AR expression and AR pathways differ in various BC subtypes ... BC, breast cancer; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2; AR, androgen ...

Roche has announced that the FDA has expanded the approval of its PATHWAY® HER2/neu (4B5) Rabbit Monoclonal Primary Antibody test to identify HE ...

In this manuscript the authors established a novel three-dimensional culture system for stratified epithelia that allows epithelial cells to undergo epithelial-to-mesenchymal transition (EMT) and ...

Researchers have identified a method to enhance the effectiveness of a promising cancer treatment. They found that modifying ...

However, mechanistic studies to support the conclusion that mitochondrial function is increased in the tumours remain incomplete and would benefit from experiments that would directly interrogate ...

An oft-repeated message is that primary aldosteronism is not rare; it is quite common. An equally urgent message is that ...